Skip to main content

Hip Fracture

7
Pipeline Programs
11
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 12 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
1
NavigatedPhase 41 trial
Active Trials
NCT00955565Completed150Est. Jan 2010
Stamford Pharmaceuticals
2 programs
1
Ferrous sulphate tabletsPhase 31 trial
targon pft nailN/A1 trial
Active Trials
NCT02680028Completed229Est. Jun 2019
NCT00919230Completed300Est. Aug 2009
Utah Medical
Utah MedicalIreland - Dublin
2 programs
1
1
TestosteronePhase 3
AtorvastatinPhase 2Small Molecule1 trial
Active Trials
NCT02197065Completed20Est. Jan 2017
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
TestosteronePhase 31 trial
Active Trials
NCT02938923Completed129Est. Nov 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
MK0677Phase 2
Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.N/A
MSD
MSDIreland - Ballydine
2 programs
1
MK0677Phase 21 trial
Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.N/A1 trial
Active Trials
NCT00414830Unknown600Est. Sep 2009
NCT00128115Terminated83Est. Aug 2007
Merck & Co.
Merck & Co.RAHWAY, NJ
2 programs
Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.N/A
MK0677PHASE_2
Integra LifeSciences
Integra LifeSciencesAustralia - Clayton
1 program
Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAXN/A1 trial
Active Trials
NCT00703716Completed190Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsNavigated
Colorado TherapeuticsTestosterone
Stamford PharmaceuticalsFerrous sulphate tablets
Utah MedicalAtorvastatin
MSDMK0677
Stamford Pharmaceuticalstargon pft nail
Integra LifeSciencesStabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX
MSDSystematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Clinical Trials (8)

Total enrollment: 1,701 patients across 8 trials

NCT00955565Innovation PharmaceuticalsNavigated

Accuracy of Navigation in Placement of Sacroiliac Screw

Start: Jun 2008Est. completion: Jan 2010150 patients
Phase 4Completed
NCT02938923Colorado TherapeuticsTestosterone

Starting a Testosterone and Exercise Program After Hip Injury

Start: Mar 2019Est. completion: Nov 2023129 patients
Phase 3Completed
NCT00919230Stamford PharmaceuticalsFerrous sulphate tablets

Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture

Start: Jul 2004Est. completion: Aug 2009300 patients
Phase 3Completed
NCT02197065Utah MedicalAtorvastatin

Pilot Study of Atorvastatin for Orthopedic Surgery Patients

Start: Sep 2014Est. completion: Jan 201720 patients
Phase 2Completed
NCT00128115MSDMK0677

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Start: Sep 2005Est. completion: Aug 200783 patients
Phase 2Terminated
NCT02680028Stamford Pharmaceuticalstargon pft nail

Short Versus Standard Intramedullary Nail for Trochanteric Hip Fractures

Start: Nov 2015Est. completion: Jun 2019229 patients
N/ACompleted
NCT00703716Integra LifeSciencesStabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX

Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX

Start: May 2008Est. completion: Dec 2010190 patients
N/ACompleted
NCT00414830MSDSystematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Start: Jan 2005Est. completion: Sep 2009600 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.